newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

OTLKOTLKW
  • Outlook Therapeutics, Inc. commenced an underwritten public offering of common stock & accompanying warrants on August 12, 2026.
  • The company intends to grant underwriters a 30-day option to purchase up to 15% additional shares & warrants under the same terms.
  • Piper Sandler & BTIG are acting as joint bookrunning managers for the offering.
  • All securities in the proposed offering will be sold by Outlook Therapeutics.
  • Net proceeds will support the commercial launch of LYTENAVA™ in the U.S., working capital, & general corporate purposes.
  • The offering is conducted via a Form S-3 shelf registration statement originally filed on March 28, 2024, & declared effective on April 5, 2024.
  • LYTENAVA™ is the only FDA-approved ophthalmic bevacizumab formulation for wet AMD & has launched in Germany, Austria, & the UK.
  • The offering is subject to market conditions, with no assurance regarding completion, size, or final terms.